CEO Profile

Swey-Shen Chen (D.Sc.) is the founder of AAIIT. He obtained his M.S. and D.Sc in immunology, epidemiology, and molecular biology at Harvard University, taught and research as Professor at the Case Western Reserve University Medical School and the University of Nebraska at Lincoln and the University of Nebraska Medical Center at Omaha, and has worked as Principal Investigator at the La Jolla Institute and visiting PI and Professor at the Scripps Research Institute, NTU and Academia Sinica. He invented IgE immunization, leading to the launching of mAb anti-IgE Xolair and extended to CTL and Treg-based vaccines, and peanut allergy vaccines inducing long-term IgE tolerance. US Patents include: (1) Supertypes MHCIa vaccines, (2) Universal MHCIb and HLA-E and HLA-G based vaccines, (3) Peanut allergy vaccines on the nuclear receptor platform, (4) Reverse ribosome display for agonist, antagonist and inverse agonist pharmacophore, (5) Treating Gal-3 as Th17 cytokine hub, (6) Tolerogenic mRNA vaccines to treat allergic inflammation, autoimmune diseases, and cancers. Open communication and Team work and mutual respect is the Institute’s culture.

What We Do : Pipelines

1. MHCIa SUPERTYPES Vaccines and MHCIb UNIVERSAL VACCINES.

2. PEANUT ALLERGY VACCINES

3. IMMUNE SUPPRESSIVE/TOLEROGENIC mRNA FOR ALLERGY, AUTOIMMUNE DISEASES.

4. RIBOSOME DISPLAY, DARWINIAN MOLECULAR EVOLUTION, DNA SHUFFLE INBREEDING FOR DE NOVO DESIGH OF HIGH AFFINITY PROEIN AND PEPTIDE OF HIGH AFFINITY AS AGONIST, ANTAGONIST AND INVERSE AGONIST PHARMACOPHORE

Integrating the knowledge of cellular immunology, redox chemistry, regulatory biology, molecular biology, peptide chemistry, and protein scaffold technology, we are designing an innovative new generation of anti-allergy, anti-autoimmunity drugs with high efficacies and large safety margins.

AAIIT conductS research and licensing on biologics in the pipeline; MHCIa and MHC1b universal vaccines for inflammatory diseases and autoimmune diseases; peanut allergy vaccines; transcription factor-based Treg therapy for allergy and autoimmune diseases

Licensing reverse ribosome display Darwinian molecular evolution platform in de novo Darwinian design and inbreeding via DNA shuffle to provide high affinity three dimensional proteins and peptides to treat Allergy, autoimmune diseases, and inflammatory diseases.